When the IOVA CEO says that a clinical trial's results "may be even more than what people are expecting in this space" ....you fucking sit up and pay attention. The @IovanceBio Q2 earning call literally leaked a preview of how good the upcoming trial results are going to be. There were 16 notable quotes worth paying attention to giving a hint that TIL therapy is going to continue to be a major revenue driver as its durability, safety and efficacy continue to exceed expectations...not only for melanoma, but for non-small cell lung cancer, sarcoma and endometrial solid tumors as well.(CryptoCondom)